Biomedicine. Lowering LDL--not only how low, but how long?
Brown
Michael S
MS
Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9046, USA. mike.brown@utsouthwestern.edu
Goldstein
Joseph L
JL
D001741:Black or African American / Q000235:genetics; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D018389:Codon, Nonsense; D003327:Coronary Disease / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D018752:Diet, Fat-Restricted; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015994:Incidence; D008077:Lipoproteins, LDL / Q000097:blood*; D051379:Mice; D020125:Mutation, Missense; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases / Q000235:genetics* / Q000378:metabolism*; D013997:Time Factors; D044465:White People / Q000235:genetics
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D018389:Codon, Nonsense; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; C472125:PCSK9 protein, human; C472126:Pcsk9 protein, mouse; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases